Home > Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one in the framework of the Council Decision on new psychoactive substances.

European Monitoring Centre for Drugs and Drug Addiction. (2014) Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one in the framework of the Council Decision on new psychoactive substances. Luxembourg: Office for Official Publications of the European Communities.

[img]
Preview
PDF (Risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one) - Published Version
3MB

This report presents the data and findings of the risk assessment on the new psychoactive substance, 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one, that was conducted by the Scientific Committee of the EMCDDA. Concerns over this stimulant drug in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.

MDPV is a ring-substituted synthetic derivative of cathinone chemically related to pyrovalerone, both of which are subject to control under the 1971 United Nations Convention on Psychotropic Substances. MDPV has potent cocaine-like stimulant properties.


Item Type
Report
Publication Type
International, Report
Drug Type
New psychoactive substance
Intervention Type
Harm reduction, Screening / Assessment
Date
May 2014
Pages
153 p.
Publisher
Office for Official Publications of the European Communities
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)

Repository Staff Only: item control page